B cell depletion in treating primary biliary cirrhosis: Pros and cons

World Journal of Gastroenterology

Volumn 18, Issue 30, 2012, Pages 3938-3940

  Yin, Yu Feng ^a   Zhang, Xuan ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Anti mitochondrial antibodies; B cell depletion; Primary biliary cirrhosis; Rituximab

Indexed keywords

ALKALINE PHOSPHATASE; CASPASE; CD20 ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MITOCHONDRION ANTIBODY; RITUXIMAB; TRANSFORMING GROWTH FACTOR; URSODEOXYCHOLIC ACID;

ANTIBODY TITER; ARTICLE; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; HERPES ZOSTER; HUMAN; HUMORAL IMMUNE DEFICIENCY; NONHUMAN; PRIMARY BILIARY CIRRHOSIS; UPPER RESPIRATORY TRACT INFECTION;

EID: 84871518635     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v18.i30.3938     Document Type: Article

References (32)

1. Tsuda M, Moritoki Y, Lian ZX, Zhang W, Yoshida K, Wakabayashi K, Yang GX, Nakatani T, Vierling J, Lindor K, Gershwin ME, Bowlus CL. Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Hepatology 2012; 55: 512-521
2. Kamihira T, Shimoda S, Harada K, Kawano A, Handa M, Baba E, Tsuneyama K, Nakamura M, Ishibashi H, Nakanuma Y, Gershwin ME, Harada M. Distinct costimulation dependent and independent autoreactive T-cell clones in primary biliary cirrhosis. Gastroenterology 2003; 125: 1379-1387
3. Van de Water J, Cooper A, Surh CD, Coppel R, Danner D, Ansari A, Dickson R, Gershwin ME. Detection of autoantibodies to recombinant mitochondrial proteins in patients with primary biliary cirrhosis. N Engl J Med 1989; 320: 1377-1380
4. Talwalkar JA, Lindor KD. Primary biliary cirrhosis. Lancet 2003; 362: 53-61
5. Nakanuma Y. Distribution of B lymphocytes in nonsuppurative cholangitis in primary biliary cirrhosis. Hepatology 1993; 18: 570-575
6. Moteki S, Leung PS, Dickson ER, Van Thiel DH, Galperin C, Buch T, Alarcon-Segovia D, Kershenobich D, Kawano K, Coppel RL. Epitope mapping and reactivity of autoantibodies to the E2 component of 2-oxoglutarate dehydrogenase complex in primary biliary cirrhosis using recombinant 2-oxoglutarate dehydrogenase complex. Hepatology 1996; 23: 436-444
7. Ichiki Y, Shimoda S, Hara H, Shigematsu H, Nakamura M, Hayashida K, Ishibashi H, Niho Y. Analysis of T-cell receptor beta of the T-cell clones reactive to the human PDC-E2 163-176 peptide in the context of HLA-DR53 in patients with primary biliary cirrhosis. Hepatology 1997; 26: 728-733
8. Dhirapong A, Lleo A, Yang GX, Tsuneyama K, Dunn R, Kehry M, Packard TA, Cambier JC, Liu FT, Lindor K, Coppel RL, Ansari AA, Gershwin ME. B cell depletion therapy exacerbates murine primary biliary cirrhosis. Hepatology 2011; 53: 527-535
9. Kurosaki T. Paradox of B cell-targeted therapies. J Clin Invest 2008; 118: 3260-3263
10. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, McGee PF, Moran AM, Raskin P, Rodriguez H, Schatz DA, Wherrett D, Wilson DM, Lachin JM, Skyler JS. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009; 361: 2143-2152
11. Winter MC, Hancock BW. Ten years of rituximab in NHL. Expert Opin Drug Saf 2009; 8: 223-235
12. Maloney DG, Press OW. Newer treatments for non-Hodgkin's lymphoma: monoclonal antibodies. Oncology (Williston Park) 1998; 12: 63-76
13. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572-2581
14. Gómez-Puerta JA, Quintana LF, Stone JH, Ramos-Casals M, Bosch X. B-cell depleting agents for ANCA vasculitides: A new therapeutic approach. Autoimmun Rev 2012; 11: 646-652
15. Agarwal SK. Biologic agents in rheumatoid arthritis: an update for managed care professionals. J Manag Care Pharm 2011; 17: S14-S18
16. Moritoki Y, Lian ZX, Lindor K, Tuscano J, Tsuneyama K, Zhang W, Ueno Y, Dunn R, Kehry M, Coppel RL, Mackay IR, Gershwin ME. B-cell depletion with anti-CD20 ameliorates autoimmune cholangitis but exacerbates colitis in transforming growth factor-beta receptor II dominant negative mice. Hepatology 2009; 50: 1893-1903
17. Popa C, Leandro MJ, Cambridge G, Edwards JC. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Rheumatology (Oxford) 2007; 46: 626-630
18. Edwards JC, Leandro MJ, Cambridge G. B lymphocyte depletion therapy with rituximab in rheumatoid arthritis. Rheum Dis Clin North Am 2004; 30: 393-403, viii
19. Conti F, Ceccarelli F, Perricone C, Alessandri C, Conti V, Massaro L, Truglia S, Spinelli FR, Spadaro A, Valesini G. Rituximab infusion-related adverse event rates are lower in patients with systemic lupus erythematosus than in those with rheumatoid arthritis. Rheumatology (Oxford) 2011; 50: 1148-1152
20. Gong Q, Ou Q, Ye S, Lee WP, Cornelius J, Diehl L, Lin WY, Hu Z, Lu Y, Chen Y, Wu Y, Meng YG, Gribling P, Lin Z, Nguyen K, Tran T, Zhang Y, Rosen H, Martin F, Chan AC. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 2005; 174: 817-826
21. Miyakawa H, Tanaka A, Kikuchi K, Matsushita M, Kitazawa E, Kawaguchi N, Fujikawa H, Gershwin ME. Detection of antimitochondrial autoantibodies in immunofluorescent AMA-negative patients with primary biliary cirrhosis using recombinant autoantigens. Hepatology 2001; 34: 243-248
22. Williams R, Gershwin ME. How, why, and when does primary biliary cirrhosis recur after liver transplantation? Liver Transpl 2007; 13: 1214-1216
23. Kim WR, Poterucha JJ, Jorgensen RA, Batts KP, Homburger HA, Dickson ER, Krom RA, Wiesner RH, Lindor KD. Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursodeoxycholic acid therapy and liver transplantation. Hepatology 1997; 26: 22-26
24. Invernizzi P, Crosignani A, Battezzati PM, Covini G, De Valle G, Larghi A, Zuin M, Podda M. Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and-negative primary biliary cirrhosis. Hepatology 1997; 25: 1090-1095
25. Liu B, Shi XH, Zhang FC, Zhang W, Gao LX. Antimitochondrial antibody-negative primary biliary cirrhosis: a subset of primary biliary cirrhosis. Liver Int 2008; 28: 233-239
26. Jin Q, Moritoki Y, Lleo A, Tsuneyama K, Invernizzi P, Moritoki H, Kikuchi K, Lian ZX, Hirschfield GM, Ansari AA, Coppel RL, Gershwin ME, Niu J. Comparative analysis of portal cell infiltrates in antimitochondrial autoantibody-positive versus antimitochondrial autoantibody-negative primary biliary cirrhosis. Hepatology 2012; 55: 1495-1506
27. Matsumura S, Van De Water J, Leung P, Odin JA, Yamamoto K, Gores GJ, Mostov K, Ansari AA, Coppel RL, Shiratori Y, Gershwin ME. Caspase induction by IgA antimitochondrial antibody: IgA-mediated biliary injury in primary biliary cirrhosis. Hepatology 2004; 39: 1415-1422
28. Takahashi T, Miura T, Nakamura J, Yamada S, Miura T, Yanagi M, Matsuda Y, Usuda H, Emura I, Tsuneyama K, He XS, Gershwin ME. Plasma cells and the chronic nonsuppurative destructive cholangitis of primary biliary cirrhosis. Hepatology 2012; 55: 846-855
29. Stasi R. Rituximab in autoimmune hematologic diseases: not just a matter of B cells. Semin Hematol 2010; 47: 170-179
30. Freeman HJ. Colitis associated with biological agents. World J Gastroenterol 2012; 18: 1871-1874
31. Calderón-Gómez E, Panés J. Rituximab in active ulcerative colitis. Gastroenterology 2012; 142: 174-176
32. Polido-Pereira J, Rodrigues AM, Canhão H, Saraiva F, da Silva JA, Fonseca JE. Primary biliary cirrhosis in a rheumatoid arthritis patient treated with rituximab, a case-based review. Clin Rheumatol 2012; 31: 385-389